6270 results
Cited 14 times since 2019 (2.3 per year)
source: EuropePMC
Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology,
Volume 41, 1 1 2019, Pages 29-37
The role of hemodynamics in bicuspid aortopathy: a histopathologic study.
Grewal N, Girdauskas E, DeRuiter M, Goumans MJ, Poelmann RE, Klautz RJM, Gittenberger-de Groot AC
Background: A bicuspid aortic valve (BAV) is the most common congenital cardiac malformation and is associated with ascending aortic dilation in 60%-80% of patients. In this study, we aimed to address the role of hemodynamic influences on the development of aortopathy in BAV patients. Patient and methods: BAV (n=36) and tricuspid aortic valve (TAV) patients (n=17) undergoing aortic valve replacement underwent preoperative flow magnetic resonance imaging (MRI) assessment to detect the area of max...
Abstract
Cited 23 times since 2019 (3.9 per year)
source: EuropePMC
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Volume 34, Issue 4, 1 1 2019, Pages 650-659
Low thyroid function is not associated with an accelerated deterioration in renal function.
Meuwese CL, van Diepen M, Cappola AR, Sarnak MJ, Shlipak MG, Bauer DC, Fried LP, Iacoviello M, Vaes B, Degryse J, Khaw KT, Luben RN, Åsvold BO, Bjøro T, Vatten LJ, de Craen AJM, Trompet S, Iervasi G, Molinaro S, Ceresini G, Ferrucci L, Dullaart RPF, Bakker SJL, Jukema JW, Kearney PM, Stott DJ, Peeters RP, Franco OH, Völzke H, Walsh JP, Bremner A, Sgarbi JA, Maciel RMB, Imaizumi M, Ohishi W, Dekker FW, Rodondi N, Gussekloo J, den Elzen WPJ, Thyroid Studies Collaboration
Background: Chronic kidney disease (CKD) is frequently accompanied by thyroid hormone dysfunction. It is currently unclear whether these alterations are the cause or consequence of CKD. This study aimed at studying the effect of thyroid hormone alterations on renal function in cross-sectional and longitudinal analyses in individuals from all adult age groups. Methods: Individual participant data (IPD) from 16 independent cohorts having measured thyroid stimulating hormone, free thyroxine levels...
Abstract
Cited 13 times since 2019 (2.2 per year)
source: EuropePMC
Toxicological sciences : an official journal of the Society of Toxicology,
Volume 168, Issue 2, 1 1 2019, Pages 519-534
Dose Effects of Ammonium Perfluorooctanoate on Lipoprotein Metabolism in APOE*3-Leiden.CETP Mice.
Pouwer MG, Pieterman EJ, Chang SC, Olsen GW, Caspers MPM, Verschuren L, Jukema JW, Princen HMG
Epidemiological studies have reported positive associations between serum perfluorooctanoic acid (PFOA) and total and non-high-density lipoprotein cholesterol (non-HDL-C) although the magnitude of effect of PFOA on cholesterol lacks consistency. The objectives of this study were to evaluate the effect of PFOA on plasma cholesterol and triglyceride metabolism at various plasma PFOA concentrations relevant to humans, and to elucidate the mechanisms using APOE*3-Leiden.CETP mice, a model with a hum...
Abstract
Cited 41 times since 2019 (6.9 per year)
source: EuropePMC
Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology,
Volume 21, Issue 4, 1 1 2019, Pages 581-589
Cryoballoon vs. radiofrequency ablation for atrial fibrillation: a study of outcome and safety based on the ESC-EHRA atrial fibrillation ablation long-term registry and the Swedish catheter ablation registry.
Mörtsell D, Arbelo E, Dagres N, Brugada J, Laroche C, Trines SA, Malmborg H, Höglund N, Tavazzi L, Pokushalov E, Stabile G, Blomström-Lundqvist C, ESC-EHRA Atrial Fibrillation Ablation Long-Term Registry investigators
Aims: Pulmonary vein isolation (PVI), the standard for atrial fibrillation (AF) ablation, is most commonly applied with radiofrequency (RF) energy, although cryoballoon technology (CRYO) has gained widespread use. The aim was to compare the second-generation cryoballoon and the irrigated RF energy regarding outcomes and safety. Methods and results: Of 4657 patients undergoing their first AF ablation, 982 with CRYO and 3675 with RF energy were included from the Swedish catheter ablation registry...
Abstract
Cited 4 times since 2019 (0.7 per year)
source: EuropePMC
Journal of orthopaedic trauma,
Volume 33, Issue 4, 1 1 2019, Pages e124-e130
Ultrasound-Guided Nerve Blocks as Analgesia for Nonoperative Management of Distal Radius Fractures-Two Consecutive Randomized Controlled Trials.
Siebelt M, Hartholt KA, van Winden DFM, Boot F, Papathanasiou D, Verdouw BC, de Vries MR, Mathijssen NM, Kraan GA
Objectives: To investigate whether a conventional fracture hematoma block (FHB) or an ultrasound-guided peripheral nerve block has more superior analgesic effect during nonoperative management of distal radius fractures in an emergency department setting. Two peripheral nerve block types were investigated, one at the level of the elbow, or cubital nerve block (CNB), and another an axillary nerve block (ANB). Design: Two prospective randomized controlled studies were performed to compare the diff...
Abstract
Cited 6 times since 2019 (1 per year)
source: EuropePMC
Journal of cardiovascular electrophysiology,
Volume 30, Issue 6, 29 5 2019, Pages 902-909
Optimizing ablation duration using dormant conduction to reveal incomplete isolation with the second generation cryoballoon: A randomized controlled trial.
Keçe F, de Riva M, Naruse Y, Alizadeh Dehnavi R, Wijnmaalen AP, Schalij MJ, Zeppenfeld K, Trines SA
Introduction: Efficacy of cryoballoon ablation depends on balloon-tissue contact and ablation duration. Prolonged duration may increase extracardiac complications. The aim of this study is to determine the optimal additional ablation duration after acute pulmonary vein isolation (PVI). Methods: Consecutive patients with paroxysmal AF were randomized to three groups according to additional ablation duration (90, 120, or 150 seconds) after acute PVI (time-to-isolation). Primary outcome was reconne...
Abstract
Cited 9 times since 2019 (1.5 per year)
source: EuropePMC
Nutrition, metabolism, and cardiovascular diseases : NMCD,
Volume 29, Issue 7, 28 4 2019, Pages 728-735
The role of inflammation in the association between overall and visceral adiposity and subclinical atherosclerosis.
Christen T, Trompet S, Rensen PCN, Willems van Dijk K, Lamb HJ, Jukema JW, Rosendaal FR, le Cessie S, de Mutsert R
Background and aims: Inflammation may underlie the association between obesity, atherosclerosis and cardiovascular disease. We investigated to what extent markers of inflammation mediate associations between overall and visceral body fat and subclinical atherosclerosis. Methods and results: In this cross-sectional analysis of the Netherlands Epidemiology of Obesity study we estimated total body fat (TBF) by bio-impedance analysis, carotid artery intima media thickness (cIMT) by ultrasound, C-rea...
Abstract
Cited 44 times since 2019 (7.3 per year)
source: EuropePMC
Blood reviews,
Volume 35, 25 4 2019, Pages 59-67
Atrial fibrillation and cancer - An unexplored field in cardiovascular oncology.
Chu G, Versteeg HH, Verschoor AJ, Trines SA, Hemels MEW, Ay C, Huisman MV, Klok FA
An increasing body of evidence suggests an association between cancer and atrial fibrillation (AF). The exact magnitude and underlying mechanism of this association are however unclear. Cancer-related inflammation, anti-cancer treatment and other cancer-related comorbidities are proposed to affect atrial remodelling, increasing the susceptibility of cancer patients for developing AF. Moreover, cancer is assumed to modify the risk of thromboembolisms and bleeding. A thorough and adequate understa...
Abstract
International journal of cardiology,
Volume 287, 22 4 2019, Pages 211
Corrigendum to "Dexamethasone-eluting stents for the prevention of in-stent restenosis: Evidence for a differential effect in insulin-dependent and non-insulin-dependent diabetic patients" [Int. J. Cardiol. 124 (2008) 166-171].
van der Hoeven BL, Pires NMM, Warda HM, Putter H, Quax PHA, Schalij MJ, Jukema JW
Abstract
Cited 14 times since 2019 (2.3 per year)
source: EuropePMC
Circulation. Genomic and precision medicine,
Volume 12, Issue 4, 21 3 2019, Pages e002470
Subsequent Event Risk in Individuals With Established Coronary Heart Disease.
Patel RS, Tragante V, Schmidt AF, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Allayee H, Almgren P, Alver M, Baranova EV, Behloui H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dubé MP, Dufresne L, Eriksson N, Foco L, Scholz M, Gijsberts CM, Glinge C, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kotti S, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, Van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Al Ali L, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Engstrøm T, Fitzpatrick N, Fox K, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton-Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ
Background: The Genetics of Subsequent Coronary Heart Disease (GENIUS-CHD) consortium was established to facilitate discovery and validation of genetic variants and biomarkers for risk of subsequent CHD events, in individuals with established CHD. Methods: The consortium currently includes 57 studies from 18 countries, recruiting 185 614 participants with either acute coronary syndrome, stable CHD, or a mixture of both at baseline. All studies collected biological samples and followed-up study p...
Abstract
Cited 14 times since 2019 (2.3 per year)
source: EuropePMC
Circulation. Genomic and precision medicine,
Volume 12, Issue 4, 21 3 2019, Pages e002471
Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events.
Patel RS, Schmidt AF, Tragante V, McCubrey RO, Holmes MV, Howe LJ, Direk K, Åkerblom A, Leander K, Virani SS, Kaminski KA, Muehlschlegel JD, Dubé MP, Allayee H, Almgren P, Alver M, Baranova EV, Behlouli H, Boeckx B, Braund PS, Breitling LP, Delgado G, Duarte NE, Dufresne L, Eriksson N, Foco L, Gijsberts CM, Gong Y, Hartiala J, Heydarpour M, Hubacek JA, Kleber M, Kofink D, Kuukasjärvi P, Lee VV, Leiherer A, Lenzini PA, Levin D, Lyytikäinen LP, Martinelli N, Mons U, Nelson CP, Nikus K, Pilbrow AP, Ploski R, Sun YV, Tanck MWT, Tang WHW, Trompet S, van der Laan SW, van Setten J, Vilmundarson RO, Viviani Anselmi C, Vlachopoulou E, Boerwinkle E, Briguori C, Carlquist JF, Carruthers KF, Casu G, Deanfield J, Deloukas P, Dudbridge F, Fitzpatrick N, Gigante B, James S, Lokki ML, Lotufo PA, Marziliano N, Mordi IR, Muhlestein JB, Newton Cheh C, Pitha J, Saely CH, Samman-Tahhan A, Sandesara PB, Teren A, Timmis A, Van de Werf F, Wauters E, Wilde AAM, Ford I, Stott DJ, Algra A, Andreassi MG, Ardissino D, Arsenault BJ, Balla
Background: Genetic variation at chromosome 9p21 is a recognized risk factor for coronary heart disease (CHD). However, its effect on disease progression and subsequent events is unclear, raising questions about its value for stratification of residual risk. Methods: A variant at chromosome 9p21 (rs1333049) was tested for association with subsequent events during follow-up in 103 357 Europeans with established CHD at baseline from the GENIUS-CHD (Genetics of Subsequent Coronary Heart Disease) Co...
Abstract
Cited 2 times since 2019 (0.3 per year)
source: EuropePMC
Frontiers in physiology,
Volume 10, 19 3 2019, Pages 225
Wall Shear Stress Directional Abnormalities in BAV Aortas: Toward a New Hemodynamic Predictor of Aortopathy?
Grewal N, Gittenberger-de Groot AC
Abstract
Cited 1 times since 2019 (0.2 per year)
source: EuropePMC
JMIR cardio,
Volume 3, Issue 1, 19 3 2019, Pages e9894
Mobile Health for Central Sleep Apnea Screening Among Patients With Stable Heart Failure: Single-Cohort, Open, Prospective Trial.
Treskes RW, Maan AC, Verwey HF, Schot R, Beeres SLMA, Tops LF, Tops LF, Van Der Velde ET, Schalij MJ, Slats AM
Background: Polysomnography is the gold standard for detection of central sleep apnea in patients with stable heart failure. However, this procedure is costly, time consuming, and a burden to the patient and therefore unsuitable as a screening method. An electronic health (eHealth) app to measure overnight oximetry may be an acceptable screening alternative, as it can be automatically analyzed and is less burdensome to patients. Objective: This study aimed to assess whether overnight pulse oxime...
Abstract
Pacing and clinical electrophysiology : PACE,
Volume 42, Issue 6, 19 3 2019, Pages 759
Atrial fibrillation history impact on catheter ablation outcome.
Stabile G, Trines SA, Blomström Lundqvist C, ESC-EHRA Atrial Fibrillation Ablation Long-Term Registry investigators
Abstract
Cited 69 times since 2019 (11.5 per year)
source: EuropePMC
Journal of the American College of Cardiology,
Volume 74, Issue 9, 18 3 2019, Pages 1167-1176
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial.
Jukema JW, Szarek M, Zijlstra LE, de Silva HA, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Karpov Y, Moryusef A, Pordy R, Prieto JC, Roe MT, White HD, Zeiher AM, Schwartz GG, Steg PG, ODYSSEY OUTCOMES Committees and Investigators
Background: Patients with acute coronary syndrome (ACS) and concomitant noncoronary atherosclerosis have a high risk of major adverse cardiovascular events (MACEs) and death. The impact of lipid lowering by proprotein convertase subtilisin-kexin type 9 inhibition in such patients is undetermined. Objectives: This pre-specified analysis from ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) determined whether polyvascular di...
Abstract
Cited 17 times since 2019 (2.8 per year)
source: EuropePMC
The British journal of surgery,
Volume 106, Issue 5, 18 3 2019, Pages 523-533
Meta-analysis of long-term survival after elective endovascular or open repair of abdominal aortic aneurysm.
Bulder RMA, Bastiaannet E, Hamming JF, Lindeman JHN
Background: Endovascular aneurysm repair (EVAR) has become the preferred strategy for elective repair of abdominal aortic aneurysm (AAA) for many patients. However, the superiority of the endovascular procedure has recently been challenged by reports of impaired long-term survival in patients who underwent EVAR. A systematic review of long-term survival following AAA repair was therefore undertaken. Methods: A systematic review was performed according to PRISMA guidelines. Articles reporting sho...
Abstract
Cited 55 times since 2019 (9.2 per year)
source: EuropePMC
Circulation,
Volume 139, Issue 23, 18 3 2019, Pages 2628-2638
Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients.
Jukema JW, Timal RJ, Rotmans JI, Hensen LCR, Buiten MS, de Bie MK, Putter H, Zwinderman AH, van Erven L, Krol-van Straaten MJ, Hommes N, Gabreëls B, van Dorp W, van Dam B, Herzog CA, Schalij MJ, Rabelink TJ, ICD2 Trial Investigators
Background: Patients with end-stage renal disease who are undergoing dialysis are reported to be at high risk of sudden cardiac death (SCD), and to date, no therapy has been shown to be effective in reducing this risk. The feasibility and value of prophylactic implantable cardioverter-defibrillator (ICD) implantation to prevent SCD is uncertain. Methods: We conducted the ICD2 trial (Implantable Cardioverter-Defibrillator in Dialysis Patients), a prospective, randomized, controlled study investig...
Abstract
Cited 111 times since 2019 (18.5 per year)
source: EuropePMC
JACC. Cardiovascular imaging,
Volume 13, Issue 1 Pt 1, 17 3 2019, Pages 97-105
1-Year Impact on Medical Practice and Clinical Outcomes of FFR<sub>CT</sub>: The ADVANCE Registry.
Patel MR, Nørgaard BL, Fairbairn TA, Nieman K, Akasaka T, Berman DS, Raff GL, Hurwitz Koweek LM, Pontone G, Kawasaki T, Sand NPR, Jensen JM, Amano T, Poon M, Øvrehus KA, Sonck J, Rabbat MG, Mullen S, De Bruyne B, Rogers C, Matsuo H, Bax JJ, Leipsic J
Objectives: The 1-year data from the international ADVANCE (Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care) Registry of patients undergoing coronary computed tomography angiography (CTA) was used to evaluate the relationship of fractional flow reserve derived from coronary CTA (FFRCT) with downstream care and clinical outcomes. Background: Guidelines for management of chest pain using noninvasive imaging pathways are based on short- to intermediate-term outcomes. Methods: Pati...
Abstract
Cited 4 times since 2019 (0.7 per year)
source: EuropePMC
Journal of cardiac surgery,
Volume 34, Issue 5, 13 2 2019, Pages 285-292
Outcomes after Ross procedure in adult patients: A meta-analysis and microsimulation.
Sibilio S, Koziarz A, Belley-Côté EP, McClure GR, MacIsaac S, Reza SJ, Um KJ, Lengyel A, Mendoza P, Alsagheir A, Alraddadi H, Gupta S, Schneider AW, Patel PM, Brown JW, Chu MWA, Peterson MD, Ouzounian M, Paparella D, El-Hamamsy I, Whitlock RP
Objective: We conducted a meta-analysis to estimate the risk of adverse events, life expectancy, and event-free life expectancy after the Ross procedure in adults. Methods: We searched databases for reports evaluating the Ross procedure in patients aged more than or equal to 16 years of age. A microsimulation model was used to evaluate age- and gender-specific life expectancy for patients undergoing the Ross procedure. Results: Data were pooled from 63 articles totaling 19 155 patients from 20 c...
Abstract
Cited 1 times since 2019 (0.2 per year)
source: EuropePMC
Heart, lung & circulation,
Volume 28, Issue 9, 8 2 2019, Pages 1384-1399
Echocardiography in Transcatheter Aortic Valve Replacement.
Vollema EM, Delgado V, Bax JJ
Transcatheter aortic valve replacement (TAVR) is a safe and efficient alternative for surgical valve aortic replacement in patients with symptomatic severe aortic stenosis who are inoperable or have a high risk for surgery. Randomised clinical trials have shown that TAVR is not inferior to surgical aortic valve replacement in intermediate-risk patients and ongoing trials will demonstrate the effects of TAVR in asymptomatic severe aortic stenosis patients and in patients with heart failure and mo...
Abstract
